Compare ON Holding AG (ONON) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ON Holding AG vs Summit Therapeutics Inc — how do they compare? ON Holding AG trades at $36.73 (market cap $12.41B), while Summit Therapeutics Inc trades at $14.78 (market cap $11.34B). The key difference: ON Holding AG and Summit Therapeutics Inc are close in size by market cap, and ON Holding AG is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ONON | SMMT | |
|---|---|---|
Market Cap | $12.41B | $11.34B |
Sector | Technology | Health |
52-Week High | $51.75 | $29.32 |
52-Week Low | $31.88 | $13.05 |
Enterprise Value | $11.73B | $10.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONON trades at $37.65, up 1.21% today, with a bullish technical trend and strong support at $37. The company shows robust fundamentals with Q1 2026 EPS of $0.47 beating expectations, revenue of $3.01B in 2025, and a net income margin of 8.02%. Analyst sentiment is highly positive, with 76.92% recommending Buy and a consensus price target of $47.33, indicating significant upside potential from current levels.
Outlook remains favorable driven by earnings beats and margin expansion, but risks include high valuation multiples like a P/E of 40.62 and competitive pressures in the athletic apparel sector. The stock's growth trajectory hinges on sustaining innovation and market share gains amid economic uncertainties.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
